A detailed history of Royal Fund Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Royal Fund Management, LLC holds 44,182 shares of VKTX stock, worth $1.44 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
44,182
Previous 1,000 4318.2%
Holding current value
$1.44 Million
Previous $63,000 2720.63%
% of portfolio
0.17%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 16, 2025

BUY
$38.28 - $78.03 $1.24 Million - $2.53 Million
32,438 Added 276.21%
44,182 $1.78 Million
Q3 2024

Oct 08, 2024

BUY
$49.84 - $70.47 $17,144 - $24,241
344 Added 3.02%
11,744 $743,000
Q2 2024

Jul 18, 2024

BUY
$47.39 - $80.2 $540,246 - $914,280
11,400 New
11,400 $604,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.5B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Royal Fund Management, LLC Portfolio

Follow Royal Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Royal Fund Management, LLC with notifications on news.